'Pretty striking': Pfizer results prompt calls for Australian investment in new technology

  • 📰 smh
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 80%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Strong early results from Pfizer and BioNTech's phase 3 coronavirus vaccine trial have been welcomed by local vaccine experts, promoting renewed calls for Australia to invest in new types of vaccine manufacturing technology | MsEmmaK

She warned there were still key unknowns about the results, however, including how long the protection against the virus might last and whether some cohorts of trial participants may not be seeing benefits from the vaccine.

The Pfizer product, known as BNT162b2, has already been granted a provisional determination by Australia's Therapeutic Goods Administration, which paves the way for Pfizer to apply for a provisional registration of the product.and began this process on Monday. CSL will also make the University of Queensland's vaccine if it passes trials.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

MsEmmaK Hang on, can you verify this story? Apparently 40K people with covid, 94 patients were chosen of which 8 received the vaccine (the others placebo). Before we start talking about a vaccine for billions of people let’s get a bit of perspective first.....

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 6. in İD

Indonesia Berita Terbaru, Indonesia Berita utama